The risk of venous thromboembolism (VTE) is increased after a myocardial infarction (MI). Some prothrombotic genotypes associated with VTE have also been associated with risk of MI. Whether prothrombotic single-nucleotide polymorphisms (SNPs) further increase the risk of VTE in MI patients is scarcely investigated.
Essentials
• The risk of venous thromboembolism (VTE) is increased after myocardial infarction (MI).
• Whether this association is explained by common prothrombotic genotypes is scarcely investigated.
• We investigated the combined impact of MI and prothrombotic genotypes on risk of VTE.
• In patients with MI, prothrombotic genotypes did not yield excess risk of VTE.
| INTRODUCTION
Several studies have indicated that patients with myocardial infarction (MI) have increased risk of subsequent venous thromboembolism (VTE). [1] [2] [3] The risk is highest during the first months after an MI 2,3 and appears to be particularly pronounced for pulmonary embolism (PE).
VTE is a multicausal disease encompassing both genetic and environmental risk factors, and a number of prothrombotic genotypes have been linked with VTE risk. 4 In a prediction study, de Haan and coworkers 5 investigated whether a set of 31 known VTE-associated single-nucleotide polymorphisms (SNPs) could be used to identify subjects with high risk of VTE. SNPs with the highest odds ratios in the literature were added one by one to build a risk score, ultimately using the most parsimonious model. A 5-SNP score, which consisted of rs8176719 (ABO), rs6025 (F5, factor V Leiden [FVL]), rs1799963 (F2, prothrombin G20210A), rs2066865 (FGG), and rs2036914 (F11), predicted VTE with an area under the receiver operating characteristic curve of 0.69.
The mechanism for the relationship between MI and VTE is not well understood. However, growing evidence indicates that atherosclerotic risk factors 6, 7 and subclinical atherosclerosis [8] [9] [10] [11] are not associated with VTE, and therefore cannot serve as common risk factors for the 2 conditions. It has been reported that certain SNPs associated with VTE risk also predisposes to acute MI. 5, [12] [13] [14] [15] Additionally, family history of MI has been demonstrated to be a risk factor for VTE in several studies, [16] [17] [18] and this risk is not explained by intermediate development of MI. 19 Whether the relationship between MI and VTE can be explained by common prothrombotic genotypes has not been well addressed. Therefore, the aim of this study was to investigate the combined effect of MI and the SNPs included in the 5-SNP risk score on VTE risk in a population-based case cohort.
| MATERIALS AND METHODS

| Study population
As described elsewhere, 20 Hypertension was defined as mean systolic blood pressure ≥140 mm Hg or mean diastolic blood pressure ≥90 mm Hg or current use of antihypertensives. Hypercholesterolemia was defined as total cholesterol ≥6.5 mmol/L. From the self-administered questionnaires, baseline data on diabetes mellitus, cardiovascular disease (myocardial infarction, angina, or stroke), smoking (never/former/ current), physical activity habits, and education level was obtained.
Education level was categorized into basic schooling (7-10 years), high school/vocational school, and college/university. Further information about the baseline variables in the Tromsø Study can be found elsewhere. 20 Classification of Diseases codes, as previously described. 3 The medical records were reviewed, and all possible events were validated by an independent end-point committee. MONICA/ MORGAM criteria were used to adjudicate MI cases, and these included clinical signs and symptoms of ischemic cardiac disease, findings on electrocardiograms, and elevated cardiac biomarkers.
| Assessment of myocardial infarction
The autopsy record was used when applicable.
| Prothrombotic genotypes
We genotyped the SNPs rs8176719 in ABO (ABO blood group), rs6025 in F5 (FVL), rs1799963 in F2 (prothrombin G20210A), and rs2036914 in F11 using the Sequenom platform, and rs2066865
in FGG using the TaqMan platform, as previously described. 22 For Sequenom, samples were genotyped using the Sequenom iPlex Gold Assay according to the recommended protocol, using an initial input of 10 to 20 ng DNA, and were analyzed using the MassARRAY Analyzer 4 (Agena Bioscience, San Diego, CA, USA). For TaqMan, an initial input of 100 ng of DNA was used, and samples were genotyped using the 7900HT (Applied Biosystems, Foster City, CA, USA) according to the recommended protocol.
Subjects were categorized as carriers of the prothrombotic risk gene when ≥1 risk allele was present. For rs2036914, the minor allele was associated with lower risk of VTE, and therefore we considered the major allele as the risk allele. Based on the paper by de Haan et al, 5 we composed a 5-SNP score by summarizing the number of risk alleles from the 5 sequenced SNPs. These were further categorized into 0 to 1, 2, 3, and ≥4 risk alleles.
| Statistical analysis
Statistical analysis was carried out using the STATA software version 15.0 (StataCorp, College Station, TX, USA). Cox proportional hazards regression models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE by MI status, adjusted for each of F I G U R E 1 Flowchart illustrating the composition of the case-cohort study. FVL, factor V Leiden; VTE, venous thromboembolism follow-up contributed with both unexposed and exposed person-time (ie, unexposed person-time from baseline to the date of MI, and thereafter with exposed person-time from MI to the end of follow-up). All analyses were adjusted sex. The proportional hazards assumption was tested using Schoenfeld residuals and found not violated.
| RESULTS
Baseline characteristics of the study participants are shown in Table 1 . In our cohort, 274 subjects experienced an incident MI during the median of 15.7 years of follow-up. On average, those who developed MI were older and had higher values of cardiometabolic risk factors, including total cholesterol, triglycerides, and body mass index than those who did not experience an MI. The proportion of men, smokers, and subjects with hypertension, hypercholesterolemia, and diabetes mellitus was higher in those with MI than in those without MI. The proportion of participants with ≥1 risk allele(s) for the SNPs investigated were essentially similar between the groups (Table 1 ). In subjects without MI, the risk of VTE increased linearly across increasing categories of risk alleles of the 5-SNP score.
In those with 2, 3 and ≥4 risk alleles, the risk was 1.2-fold (HR, 1.18; 95% CI, 1.00-1.54), 1.5-fold (HR, 1.47; 95% CI, 1.14-1.90) and 1.8-fold (HR, 1.78; 95% CI, 1.37-2.31) increased compared to subjects with 0 to 1 risk alleles. In patients with MI, there was no increased risk across categories of the 5-SNP score ( Table 3 and Figure 2 ).
In subgroup analysis, we found that MI patients with ≥1 risk allele at F11 had 1.8-fold higher risk of PE (HR, 1.79; 95% CI, 1.05-3.05).
Otherwise, subgroup analysis on the association between the other SNPs studied and MI in relation to the risk of DVT and PE (Table S1) , as well as provoked and unprovoked VTE, (Table S2) 
| DISCUSSION
We investigated the role of 5 prothrombotic genotypes as potential common risk factors for MI and VTE. Subjects with MI had increased risk of VTE, but adjustment for the 5 prothrombotic SNPs, either individually or as a score, did not influence this relationship.
In individuals without MI, the risk of VTE increased with increasing number of risk alleles in the 5-SNP score. In contrast, there was no association between increasing number of risk alleles and risk of VTE in MI patients. Our findings suggest that the increased risk of VTE in patients with MI cannot be explained by these 5 prothrombotic genotypes.
Several studies, 1,2 including a former report from the Tromsø Study, 3 have shown that MI patients are at increased risk of VTE, particularly the initial months after the MI. Several lines of evidence support that this relationship is not explained by common atherosclerotic risk factors or subclinical atherosclerosis. A large meta-analysis of 9 population-based cohorts, including more than 240 000 individuals, showed no association between traditional atherosclerotic risk factors and VTE. 7 In the Tromsø Study, the risk of VTE after MI remained after adjustment for atherosclerotic risk factors. 3 Moreover, previous cohorts, 11 including the Tromsø Study, 8, 9 consistently showed that subclinical atherosclerosis was not associated with VTE.
Non-O blood group, FVL, prothrombin G20210A, and SNPs in FGG and F11 are recognized risk factors for VTE, [23] [24] [25] and some of these SNPs have also been associated with coronary artery disease. 13, 14, 26, 27 For instance, non-O blood group is associated with a modestly increased risk of coronary heart disease, 28, 29 and 2 meta-analyses 14, 30 concluded that the FVL and prothrom- Our study has several strengths, such as the prospective design, recruitment of participants from a general population, well-validated events of both VTE and MI, and the long follow-up period. The high participation rate and the broad age range formed a source cohort that presumably is representative of a general Caucasian population. The study was limited by a low number of VTE events in certain subgroups, particularly for the SNPs with a low prevalence (eg, the prothrombin mutation). Hence, the risk estimates must be interpreted with caution. Further studies with more statistical power are warranted to explore this association is subgroups of MI patients. Both statins and antithrombotic medications are frequently used after MI, and these therapies also reduces the risk of VTE. Unfortunately, we lacked information on the use of medications after MI. However, the use of such medications would presumably be evenly distributed among the prothrombotic genotypes and categories of the 5-SNP score, and thus, not serve as confounders. However, if the effect of these therapies were sufficient to counterbalance the risk of VTE due to prothrombotic genotypes in MI patients, they may have contributed to dilute or underestimate the effect of prothrombotic genotypes. Finally, as in all observational studies, the potential presence of residual confounding cannot be ruled out.
The combination of MI and 5 prothrombotic genotypes, either as individual SNPs or as a 5-SNP score, did not result in an excess risk of VTE. Our findings imply that the increased risk of VTE after an acute MI is not explained by these 5 prothrombotic genotypes.
